Stocks › JNJ
Johnson & Johnson (JNJ) stock analysis
SKIP 7% confidence · analysed Oct 13, 2026
On Oct 13, 2026, our model rated Johnson & Johnson (JNJ) SKIP with 7% confidence at a price of $263.73. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 43. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (0.9x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $249.04 and the swing low is $218.03; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 2.77, which looks expensive relative to its growth.
The company reports a profit margin of 21.5% and revenue growth of +6.6%.
In its latest quarter it earned $2.90 per share, which beat the $2.85 analysts expected, with revenue +6.6% year over year.
Wall Street's average rating is 1.9 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $279.82.
The model's one-paragraph read
No clear edge (SKIP) — composite score +0.07 (SKIP). Technicals: RSI 42.53, MACD bearish, price below SMA50. Fundamentals: PEG 2.77, margin 21.5%, revenue growth 6.6%. Financial results: YoY revenue +6.6%, last EPS surprise +1.8%. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block. FinGPT news read: neutral. Memory: 28 prior look(s); 0% of directional calls matched later price. Reference price $250.2; no trade levels (SKIP).
Past ratings for JNJ
Of the last 5 directional calls on JNJ, 0 pointed the right way by the most recent analysis (0%). Past calls do not guarantee future results.
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 13, 2026 | SKIP | 7% | $263.73 | — | |
| Oct 12, 2026 | SKIP | 9% | $261.44 | +0.9% | |
| Oct 9, 2026 | SKIP | 6% | $256.48 | +2.8% | |
| Oct 7, 2026 | SKIP | 9% | $254.78 | +3.5% | |
| Oct 1, 2026 | SKIP | 8% | $262.49 | +0.5% | |
| Sep 30, 2026 | BUY | 42% | $267.57 | -1.4% | ✘ wrong direction |
| Sep 29, 2026 | SKIP | 10% | $271.95 | -3.0% | |
| Sep 28, 2026 | WEAK BUY | 15% | $272.45 | -3.2% | ✘ wrong direction |
| Sep 24, 2026 | WEAK BUY | 17% | $269.17 | -2.0% | ✘ wrong direction |
| Sep 23, 2026 | SKIP | 9% | $271.26 | -2.8% | |
| Sep 18, 2026 | WEAK BUY | 16% | $268.24 | -1.7% | ✘ wrong direction |
| Sep 17, 2026 | WEAK BUY | 16% | $267.90 | -1.6% | ✘ wrong direction |
"Move since" compares each call's price with the latest analysed price.
Recent news on JNJ
- Oct 14, 2026: J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks? (BeInCrypto)
- Oct 13, 2026: UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? (Zacks)
- Oct 13, 2026: Earnings Calendar and Analysis for This Week (Kiplinger)
- Oct 13, 2026: J&J posts weak medical device sales, shares fall (CNBC Earnings)
- Oct 13, 2026: J&J's 6% slide on an imperfect quarter is a gift to prospective buyers (CNBC Earnings)
- Oct 13, 2026: Stocks remain lower in final hour of trading. Energy and communication services limit market downside. (MarketWatch)
Other Healthcare stocks we cover
KMDA · LH · LLY · MDT · NRC · NVO · OSCR · PCRX · PGNY · PHR · PRGO · SDZNY
Frequently asked questions
Is JNJ a buy right now?
As of Oct 13, 2026, our automated model rates Johnson & Johnson (JNJ) SKIP with 7% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.